Pharmaceutical Market Europe • November 2024 • 3
COMMENT
This month, Dom Tyer looks at the explosive growth of Gen AI, saying that it “has caused plenty of consternation as well as celebration, but there’s no turning back the clock on this far-reaching technology”. He goes on to say that “there are many important considerations for commercial pharma executives if they are to benefit from the ascendence of Gen AI in life sciences, starting with the need to assess the current position of this fast-moving technology”. Find out more on page 32.
Danny Buckland’s article looks at cutting through the maze of obstacles to liberate patient pathways, and how digital and AI intelligence is advancing healthcare while demolishing barriers to access and equity. As he says: “Digital advances, both in technology and its delivery, have been remarkable in recent years but, with ten million people in the UK lacking foundation-level tech skills, there is growing concern that the groups often most in need of healthcare, such as the elderly and socially disadvantaged, remain on the outside.” Read more on page 26.
In our article from Amgen’s Russell Abberley, he looks at why the patient voice is the secret to re-energising the healthcare sector, the challenges facing the UK’s healthcare system and why putting the patient voice at the heart of our work is key. As he says: “Investing in the future of healthcare means not only improving staff and patient engagement today but thinking about the staff and patients of tomorrow.” Turn to page 16 to find out more.
In Europe, health inequity poses the greatest challenge to achieving public health goals in the coming years. In this month’s article on page 18, the authors look at how the ‘five Ps’ can close health equity gaps, with policymakers, payers, providers, patients and pharma each uniquely able to impact health equity – and together, achieve real progress.
Next month, our December issue looks at maintaining the focus on the patient – the need for a human touch in an AI world. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
And don’t forget to book your tickets for the PMEAs, taking place at a black tie event in London on 21 November. Email ddevadiga@pmlive.com to find out more.
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Deputy Editor
Emily Kimber
Studio:
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2024 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW